The identification and characterisation of the gene mutated in cystic fibrosis in 1989'-3 and the development of strategies for the genetic manipulation of mammalian cells have lead to great expectations among patients and physicians for dramatic improvements in the treatment of cystic fibrosis, and in particular have raised hopes that gene therapy for this life threatening disease may be available soon. Last year's successful expression of the normal human CFTR gene sequence (human CFTR cDNA) in the lungs of unaffected rats and mice45 and the creation of transgenic mouse models for cystic fibrosis" have given further support to the expectation ofgene therapy for cystic fibrosis. Now clinicians and scientists involved in treatment and research of cystic fibrosis have taken a further step to make these hopes become reality: in December 1992 three groups obtained approval for phase 1 clinical trials for somatic genetic therapy of cystic fibrosis from the US National Institutes of Health Recombinant DNA Advisory Committee.
Pathogenesis and pathology of cystic fibrosis
To understand the currently proposed experimental strategies for somatic gene therapy of cystic fibrosis, it is useful to recall the molecular pathogenesis of the disease. Cystic fibrosis is autosomal recessive; the gene, which causes disease when mutated codes for an integral membrane protein.
Because of its cellular function, it has been called the cystic fibrosis transmembrane conductance regulator (CFTR). 2 The main physiological role of CFTR is that of a cAMP regulated chloride channel.9 CFTR mutations lead to a disturbance of chloride transport across the luminal surface of the secretory epithelia of the gut, pancreas, lung, biliary ducts, and sperm ducts, and to a compensatory influx of sodium to retain electroneutrality. The accompanying water influx causes, according to one theory, dehydration at the cellular surface and leads to the sticky mucus characteristic of this disease.'0 Other investigators believe that increased pH in the intracellular vesicles as a result of the disturbed chloride transport causes incorrect protein glycosylation, which in turn leads to the cellular dysfunction seen in cystic fibrosis. Atypical glycosylation could lead to an increase in the number of binding sites for Pseudomonas spp, and a change of viscosity in the mucus." The secretory sweat gland cells seem to have a CFTR independent mechanism of chloride secretion, whereas an impaired ionic reabsorption in the peripheral part of the ducts is responsible for the pathognomonic salty sweat observed in cystic fibrosis patients. 12 The sticky mucus in lung, pancreas, and liver causes mechanical obstruction and chronic inflammation of airways and gut lumen, and is the basis for therapy resistant infection, particularly of the lung. Progressive respiratory failure secondary to bronchiectasis is the most common cause ofdeath, with pancreatic insufficiency, hepatic cirrhosis, and diabetes mellitus as other contributing factors. To date treatment of cystic fibrosis is symptomatic, including daily physiotherapy and antibiotics directed against respiratory infections together with pancreatic enzyme supplements and intensive dietary support of the otherwise chronically malnourished patient. More recently amiloride, DNase and alantitrypsin have been on trial as more specific treatments. However, gene therapy is now considered to be a promising long term approach to treatment for cystic fibrosis, particularly with respect to prevention of lung disease.
Approaches to gene therapy of cystic fibrosis The isolation of the coding sequence of CFTR (CFTR cDNA)2 was a prerequisite for any strategy directed towards gene therapy. The first attempts towards the correction ofthe cystic fibrosis phenotype were made on cystic fibrosis cells in culture using retroviral and vaccinia/T7 systems for transfer and expression of CFTR-cDNA.'3'4 Successful complementation ofthe cystic fibrosis defect in vitro was assessed by restoration of normal cAMP dependent chloride transport to these cells.'3 '5 These experiments also established that only one copy of the retroviral CFTR-cDNA construct in cystic fibrosis cells is sufficient to restore normal chloride transport. No harmful effects were observed when human CFTR was expressed in transgenic mice from a lung specific promoter,'6 thereby establishing that overexpression is not a problem. It has also been shown that CFTR expression in normal lung cells is very low'7 and that the presence of less than 10% cells corrected with CFTR-cDNA in a monolayer with uncorrected cystic fibrosis cells is sufficient to restore normal chloride transport in the entire cell monolayer.' All these data provide realistic support for the concept of gene therapy for cystic fibrosis.
Somatic compared with germ line gene therapy Two general approaches to gene therapy can be considered.
Somatic gene therapy aims at the correction in a certain type or range of somatic cells expressing the affected phenotype in a particular patient; there is no attempt to correct the defect in egg or sperm cells and therefore correction is not transmit-ted to any children of an affected individual. In contrast, germ line gene therapy would lead to correction of all cells of an individual, including the germ line. This correction would, therefore, also be propagated to following generations.
At present, clinicians, scientists, and the public agree that there is no medical or ethical justification for manipulating human germ line cells. Our present knowledge of the human genome and genetic disease is not yet sufficient to assume that there are no possibilities of problems in future generations. For the monogenic disease cystic fibrosis, with a risk of one affected fetus in four offspring of a heterozygote couple, preimplantation diagnosis"9 (which would in any case be necessary to decide which fertilised eggs to correct) has made gene therapy at this level redundant. Gene therapy for cystic fibrosis, even if applied in utero for clinical reasons, will involve somatic gene correction.
Ideally somatic gene therapy for cystic fibrosis should permanently replace the affected gene by its healthy counterpart in affected cells. This is, however, not a feasible strategy for somatic gene therapy at present, because of the very low efficiency of such a replacement event (called homologous recombination) when the normal sequence is artificially introduced into a cell. All present strategies are oriented towards complementation of the two mutated alleles by addition of the normal gene sequence.
Virus mediated gene transfer systems
The presently most favoured strategy for gene therapy is to use virus DNA carrier molecules (virus vectors) into which the gene sequence of interest has been incorporated in order to allow its introduction and expression into the relevant cells. Using retroviral vectors, this approach has been successfully pursued for the treatment of adenosine deaminase deficiency by French Anderson and collaborators,20 and several trials using this vector for different strategies of cancer treatment are under way. Derivatives of adenovirus, vaccinia virus, herpes simplex virus, and adenoassociated virus are the other main viral vectors presently in experimental use for gene transfer and expression in mammalian cells. Each of these systems has its advantages and disadvantages that must be balanced against the potential benefits of gene therapy for cystic fibrosis.
Retroviruses have the principle advantage of a high rate of transfer into mammalian cells and of a possible lifelong cure because of integration into the host genome, provided they infect the relevant stem cells. However, the integration into host DNA occurs at random, which is known to have a mutagenic effect, and also leaves the remote possibility of carcinogenesis by interference with oncogenes or tumour suppressor genes. Another possible, if remote, source of danger would be the recombination of the replication incompetent and therefore harmless virus vector with contaminating helper virus (needed for virus packaging) to (unpublished data) . The DNA to be delivered will be bound to a protein of this system via polylysine bridges and will be internalised together with this complex. We are also planning to link inactivated adenovirus, which has been shown to be able to break the lysosomal wall after endocytosis,2' to the complex. This system should enable physiological uptake to occur without cell damage. The inclusion of appropriate receptor ligands should allow targeting of these complexes to specific tissues, and there should be no limit to the size of DNA construct which can be delivered.
MAMMALIAN ARTIFICIAL CHROMOSOMES
Another, more long term, approach aims at the construction of an artificial mammalian chromosome (MAC) carrying and expressing a normal CFIR gene in a large piece of natural human chromosomal DNA. Such a MAC will carry the DNA elements required for stable replication and segregation, including a centromere, telomeres, and origins ofreplication, as well as the gene ofinterest. Ultimately the MAC should be autonomously replicating, and should segregate nonrandomly in mammalian cells. It will not integrate into the host genome, thereby excluding any potential dangers connected with virus vectors, and will give permanent expression and physiological regulation.
One of the main scientific problems of this strategy is the present lack ofunderstanding ofthe structural and functional requirements of a mammalian centromere, the chromosomal element responsible for the correct segregation of chromosomes to daughter cells at cell division. Our present approach to this problem is to introduce putative mammalian centromere elements into yeast artificial chromosomes (YAC), which are then transferred to mammalian cells by fusion with yeast spheroplasts. It has been observed that yeast and YAC DNA can replicate extrachromosomally but does not segregate after transfer to mammalian cells (unpublished data). The inclusion of functional centromere DNA on the YAC should lead to segregation of the extrachromosomal DNA. Novel approaches to targeting and entry will be of particular interest for DNA of the size of a mammalian artificial chromosome, which will exceed the packaging capacity of any virus system. Ainimal models and preparation for clinical application Recently three laboratories have been successful in the creation of transgenic mice with large insertions into exon 10 of the CFTR gene.' These three knockout mutations are somewhat different from each other and cause different degrees of disease symptoms in the mice, all very similar to the pathology of cystic fibrosis in man, including abnormalities in cAMP stimulated chloride transport. Although the introduced mutations are different from those found in humans, these models will certainly have great impact by allowing new and relevant analysis of proposed pharmacological and genetic approaches to treatment of cystic fibrosis. It Effect ofincreasing doses of recombinant virus on safety and efficacy mittee in the USA, and one or two groups in Europe are preparing applications. All these trials are to be performed on the basis of fully informed consent of patients with cystic fibrosis. In each case CFTR-cDNA/adenovirus recombinants will be applied to restricted areas of the nose and bronchial epithelia. The molecular and electrophysiological effects of this 'local' in vivo gene complementation will be intensively monitored. The patients will also be investigated for any immunological reactions and any indication of virus spread within the body and to the environment. The main aim of these trials is not to obtain an individual therapeutic effect, but to gain essential information on efficacy, safety, and dose response of this system as listed in the table. These applications have still to gain FDA approval, but undoubtedly the proposed trials will be going ahead during 1993. Whatever their outcome in detail, they will certainly provide important information on the feasibility of gene therapy with the currently available adenovirus vectors and indicate necessary improvements. Although gene therapy may not be the ultimate solution for treatment of cystic fibrosis, these trials will certainly mark the beginning of a new era in the treatment of this disease, as well as providing a model for gene therapy for other single gene disorders. Auditing ofinterventions that purport to promote health is becoming an integral part of modem medical practice. Postmarketing surveillance through the BPSU study in the British Isles offers several distinct advantages over that being performed elsewhere in the world (for example, in the USA where various H influenzae type b conjugate vaccines have been offered since 1987 in a piecemeal and evolving way).
These advantages include the following:
(1) Definition of the target population is a straightforward task because of the defined date (1 October 1992) for beginning vaccination and the clear guidelines given as to who is eligible (children <4 years).
(2) The vaccination status of any particular child in the UK can usually be easily ascertained by reference to district computer records with only occasional recourse required to parent held, general practitioner, or health visitor records.
(3) The childhood immunisation programme includes a standardised approach across the UK that is centrally organised but also involves the provision of excellent peripheral support through the work of immunisation coordinators (health professionals specifically designated to advise on and promote immunisation) in each health district. 
